Medicine and Dentistry
Patient
100%
Therapeutic Procedure
33%
Platinum
30%
Non Small Cell Lung Cancer
27%
Lung Cancer
26%
Cells
21%
Arm
17%
Pemetrexed
16%
Diagnosis
16%
Combination Therapy
15%
Carboplatin
15%
Atezolizumab
14%
Neoplasm
13%
Progression Free Survival
13%
Nivolumab
13%
Epidermal Growth Factor Receptor
12%
Anaplastic Lymphoma Kinase
12%
Gemcitabine
11%
Overall Survival
11%
Left Lung
9%
Immune Checkpoint Inhibitor
9%
Epidermal Growth Factor Receptor
9%
Plasma
9%
Combination Chemotherapy
9%
Surgery
8%
Inpatient
8%
Fusion Gene
8%
Bevacizumab
8%
Metastatic Carcinoma
8%
Neuroendocrine Carcinoma
8%
Paragonimiasis
8%
Pericardium
8%
Thoracoscopy
8%
Recurrent Disease
7%
Homeobox Protein Nkx 2.1
7%
Diseases
7%
Amrubicin
7%
Toxicity
6%
Receptor Gene
6%
Calreticulin
6%
Programmed Cell Death
6%
Ipilimumab
6%
Kidney Function
6%
Paclitaxel
6%
Adenocarcinoma
6%
Analysis
5%
Antibody
5%
Lung
5%
Specimen
5%
Small Cell Lung Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
49%
Non Small Cell Lung Cancer
43%
Lung Cancer
35%
Platinum
31%
Immune Checkpoint Inhibitor
25%
Epidermal Growth Factor Receptor
19%
Pemetrexed
17%
Carboplatin
15%
Erlotinib
14%
Cytotoxic Chemotherapy
14%
Atezolizumab
14%
Progression Free Survival
14%
Bevacizumab
14%
Nivolumab
13%
Neutropenia
12%
Cisplatin
12%
Overall Survival
12%
Combination Therapy
11%
Gemcitabine
11%
Vinorelbine
11%
Docetaxel
10%
Recurrent Disease
9%
Antinuclear Antibody
8%
Metastasis
8%
Calreticulin
7%
Epidermal Growth Factor Receptor Kinase Inhibitor
7%
Homeobox Protein Nkx 2.1
7%
Diseases
7%
Fosaprepitant
7%
Amrubicin
7%
Toxicity
6%
Neoplasm
6%
Vasculotropin
6%
Ipilimumab
6%
Adverse Event
6%
Paclitaxel
6%
Monotherapy
5%
Survival
5%